NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00145002,A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL),https://clinicaltrials.gov/study/NCT00145002,,COMPLETED,To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.,NO,Adult T-cell Leukemia|Lymphoma,DRUG: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|DRUG: biweekly-CHOP with G-CSF and intrathecal prophylaxis,Overall survival,Toxicity|CR rate|Progression free survival,,Japan Clinical Oncology Group,"Ministry of Health, Labour and Welfare, Japan",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,130,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,JCOG9801|C000000066,1998-08,,2004-12,2005-09-05,,2016-09-22,"Nagasaki University Graduate School of Biomedical Science, Nagasaki, 852-8523, Japan",
